Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OPT logo OPT
Upturn stock ratingUpturn stock rating
OPT logo

Opthea Ltd (OPT)

Upturn stock ratingUpturn stock rating
$5.04
Delayed price
Profit since last BUY14.29%
upturn advisory
Regular Buy
BUY since 19 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/18/2025: OPT (3-star) is a STRONG-BUY. BUY since 19 days. Profits (14.29%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 68.35%
Avg. Invested days 35
Today’s Advisory Regular Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 801.75M USD
Price to earnings Ratio -
1Y Target Price 12.17
Price to earnings Ratio -
1Y Target Price 12.17
Volume (30-day avg) 37713
Beta 1.65
52 Weeks Range 1.79 - 6.30
Updated Date 02/18/2025
52 Weeks Range 1.79 - 6.30
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.76

Earnings Date

Report Date 2025-02-26
When Before Market
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -164535.56%

Management Effectiveness

Return on Assets (TTM) -83.43%
Return on Equity (TTM) -3383.08%

Valuation

Trailing PE -
Forward PE 6.73
Enterprise Value 758411830
Price to Sales(TTM) 3061.77
Enterprise Value 758411830
Price to Sales(TTM) 3061.77
Enterprise Value to Revenue 6083.55
Enterprise Value to EBITDA -0.73
Shares Outstanding 153887008
Shares Floating 785869249
Shares Outstanding 153887008
Shares Floating 785869249
Percent Insiders -
Percent Institutions 3.5

AI Summary

Opthea Ltd. (OPT) Stock Overview:

Company Profile:

History and Background:

Opthea Limited (OPT) is a late-stage biopharmaceutical company established in 2010. The company's headquarters are located in Melbourne, Australia. Opthea focuses on developing novel therapies for eye diseases, particularly those causing vision loss.

Core Business Areas:

Opthea's core business areas revolve around developing and commercializing drugs for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The company's lead product candidate, OPT-302, is a novel anti-VEGF therapy currently in Phase 3 clinical trials for both wet AMD and DME.

Leadership and Corporate Structure:

Opthea operates under a Board of Directors and an executive leadership team. The current CEO is Dr. Megan Baldwin, who has extensive experience in the pharmaceutical industry. The Board consists of experienced individuals with expertise in finance, medicine, business development, and regulatory affairs.

Top Products and Market Share:

Products:

  • OPT-302: This anti-VEGF therapy is Opthea's lead product candidate for treating wet AMD and DME. It is designed to offer a longer duration of action compared to existing anti-VEGF treatments.
  • OPT-401: This is a second-generation anti-VEGF therapy currently in Phase 1/2a clinical trials for treating wet AMD.

Market Share:

OPT-302 is not yet commercially available, so Opthea does not currently hold any market share. However, the market for wet AMD and DME treatments is significant. In 2022, the global market for these therapies was estimated at approximately $12 billion, with a projected growth to $18 billion by 2027.

Product Performance and Market Reception:

OPT-302 has demonstrated promising results in clinical trials, showing efficacy and safety comparable to existing anti-VEGF therapies. However, the drug's longer duration of action could offer a significant advantage over competitors.

Total Addressable Market (TAM):

The TAM for Opthea's products includes patients with wet AMD and DME globally. The estimated TAM for these indications is approximately 10 million patients.

Financial Performance:

Being a clinical-stage company, Opthea is yet to generate significant revenue. As of June 30, 2023, the company had accumulated a net loss of $262.4 million. However, Opthea has a strong cash position of $175.4 million, which is expected to support its ongoing clinical trials and operations.

Dividends and Shareholder Returns:

Opthea currently does not pay dividends as it is focused on reinvesting its resources into research and development.

Growth Trajectory:

Opthea's growth is highly dependent on the success of its lead product candidate, OPT-302. If approved, this drug could significantly impact the company's financial performance and market position. Additionally, Opthea is actively exploring new product opportunities and potential partnerships to further its growth prospects.

Market Dynamics:

The market for wet AMD and DME treatments is highly competitive, with several established players like Regeneron (REGN), Roche (RHHBY), and Bayer (BAYRY). However, Opthea's differentiated product profile with a longer duration of action positions it favorably within this competitive landscape.

Competitors:

  • Regeneron (REGN): Key product - Eylea (anti-VEGF therapy)
  • Roche (RHHBY): Key product - Lucentis (anti-VEGF therapy)
  • Bayer (BAYRY): Key product - Eylea (marketed in collaboration with Regeneron)

Market Share:

  • Regeneron: ~40%
  • Roche: ~30%
  • Bayer: ~20%
  • Opthea: currently 0%

Competitive Advantages:

  • Longer duration of action of OPT-302 compared to existing anti-VEGF therapies.
  • Potential for reduced treatment burden for patients.
  • Strong intellectual property portfolio.

Competitive Disadvantages:

  • Limited commercial experience.
  • Dependence on the success of OPT-302.

Potential Challenges and Opportunities:

Challenges:

  • Competition from established players in the market.
  • Regulatory hurdles for product approval.
  • Managing research and development costs.

Opportunities:

  • Expanding into new geographic markets.
  • Developing additional product candidates for other eye diseases.
  • Strategic partnerships with other pharmaceutical companies.

Recent Acquisitions:

Opthea has not made any acquisitions in the last three years.

AI-Based Fundamental Rating:

Based on an analysis of Opthea's financial health, market position, and future prospects, an AI-based rating system could assign a score of 7 out of 10. This rating reflects the company's promising product pipeline, strong cash position, and favorable market dynamics. However, the rating also acknowledges the company's early-stage development and dependence on the success of its lead product candidate.

Sources and Disclaimers:

This analysis used information from Opthea's website, financial reports, investor presentations, and industry reports. Please note that this information is not intended as financial advice, and you should conduct your research before making any investment decisions.

About Opthea Ltd

Exchange NASDAQ
Headquaters South Yarra, VIC, Australia
IPO Launch date 2012-04-12
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 33
Full time employees 33

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​